| __timestamp | CymaBay Therapeutics, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 14097000000 |
| Thursday, January 1, 2015 | 8871000 | 14809000000 |
| Friday, January 1, 2016 | 9645000 | 14837000000 |
| Sunday, January 1, 2017 | 12387000 | 14784000000 |
| Monday, January 1, 2018 | 14381000 | 14455000000 |
| Tuesday, January 1, 2019 | 19238000 | 14350000000 |
| Wednesday, January 1, 2020 | 17425000 | 11615000000 |
| Friday, January 1, 2021 | 23040000 | 12703000000 |
| Saturday, January 1, 2022 | 25116000 | 13677000000 |
| Sunday, January 1, 2023 | 51953000 | 14771000000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Pfizer Inc. and CymaBay Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Pfizer's SG&A expenses have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. In contrast, CymaBay's expenses have shown a more dynamic trend, increasing by over 500% from 2014 to 2023. This growth reflects CymaBay's aggressive expansion strategy, while Pfizer's consistent expenses highlight its operational efficiency. As the industry evolves, these strategies will play a pivotal role in shaping each company's financial health and market position.
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Pfizer Inc. vs Catalent, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Pfizer Inc. and Geron Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Pfizer Inc. vs Evotec SE
Biogen Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Viatris Inc. or CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Dr. Reddy's Laboratories Limited vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs CymaBay Therapeutics, Inc.
Verona Pharma plc and CymaBay Therapeutics, Inc.: SG&A Spending Patterns Compared
CymaBay Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Xencor, Inc.